Avantor (NYSE:AVTR) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of Avantor (NYSE:AVTRFree Report) in a report published on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $30.00 price objective on the stock.

Several other research analysts have also recently weighed in on AVTR. TD Cowen upped their price target on shares of Avantor from $28.00 to $31.00 and gave the company a buy rating in a report on Monday, July 29th. Robert W. Baird boosted their price objective on shares of Avantor from $26.00 to $27.00 and gave the company an outperform rating in a research report on Monday, July 29th. Morgan Stanley increased their target price on Avantor from $28.00 to $29.00 and gave the stock an overweight rating in a report on Monday, July 29th. Citigroup lowered Avantor from a buy rating to a neutral rating and cut their price target for the company from $30.00 to $23.00 in a report on Wednesday, July 10th. Finally, Stifel Nicolaus increased their price objective on Avantor from $27.00 to $28.00 and gave the stock a buy rating in a report on Monday, July 29th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and an average target price of $27.40.

Check Out Our Latest Research Report on Avantor

Avantor Stock Performance

Avantor stock opened at $25.79 on Tuesday. The company has a market cap of $17.52 billion, a PE ratio of 66.13, a PEG ratio of 2.71 and a beta of 1.32. The company has a current ratio of 1.59, a quick ratio of 1.05 and a debt-to-equity ratio of 0.89. Avantor has a 1 year low of $16.63 and a 1 year high of $28.00. The company’s 50-day moving average is $23.34 and its two-hundred day moving average is $24.10.

Avantor (NYSE:AVTRGet Free Report) last announced its quarterly earnings results on Friday, July 26th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.02. Avantor had a return on equity of 12.40% and a net margin of 5.28%. The company had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Equities analysts anticipate that Avantor will post 1.01 earnings per share for the current year.

Institutional Trading of Avantor

Several hedge funds have recently bought and sold shares of AVTR. Versant Capital Management Inc increased its stake in Avantor by 2,003.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after buying an additional 1,102 shares during the last quarter. Blue Trust Inc. increased its position in shares of Avantor by 1,830.3% during the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after acquiring an additional 1,391 shares during the last quarter. Gladius Capital Management LP bought a new stake in Avantor during the fourth quarter worth $42,000. Montag A & Associates Inc. purchased a new position in Avantor in the fourth quarter worth $43,000. Finally, TFO Wealth Partners LLC boosted its position in Avantor by 203,100.0% in the fourth quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock worth $46,000 after purchasing an additional 2,031 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Company Profile

(Get Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

See Also

Analyst Recommendations for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.